Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
S
215600
vs
K
KOSPI 200
Over the past 12 months, SillaJen Inc has underperformed KOSPI 200, delivering a return of -23% compared to KOSPI 200's +119% growth.
Stocks Performance
215600 vs KOSPI 200
Performance Gap
215600 vs KOSPI 200
Performance By Year
215600 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
SillaJen Inc
Glance View
SillaJen Inc is a South Korean biotechnology company that focuses on developing cancer treatments based on oncolytic viruses, which are engineered viruses designed to attack tumor cells while sparing healthy tissue. Its work is centered on researching and testing experimental drug candidates rather than selling a broad range of commercial medicines. The company’s main customers are not ordinary retail buyers. Its business is aimed at pharmaceutical partners, hospitals, doctors, and ultimately cancer patients, if its drug candidates are approved. SillaJen makes money through drug development programs, research partnerships, licensing deals, and, if a treatment reaches the market, sales of that therapy. What makes SillaJen different is its role in the drug value chain: it is a research-driven developer of a very specific type of cancer therapy, not a large drugmaker with many established products. That means its value comes from turning scientific research into licensed or approved treatments that other healthcare providers can use.